Evaluation of efficacy of neuroleptics in open versus double-blind trials;Aussagekraft offener studien im vergleich zu kontrollierten studien in der prufung von neuroleptika

Fortschritte der Neurologie Psychiatrie

Volumn 68, Issue 7, 2000, Pages 313-320

  Pajonk, Frank Gerald ^a   Holzbach, R ^a   Naber, D ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INTERMETHOD COMPARISON; OUTCOMES RESEARCH; PSYCHOSIS; RATING SCALE;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0033943396     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-11638     Document Type: Article

References (57)

1. Angst A, Bobon D, Engel R, Hippius H, Janzen G et al. Report on the third consensus conference on the methodology of clinical trials with antipsychotic drugs. Pharmacopsychiatry 1991; 24: 149-152
2. Sulzbacher S. Psychotropic medication with children: an evaluation of procedural biases in results of reported studies. Pediatrics 1973; 51(3): 513-517
3. Kavale K. The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis. J Learning Disabilities 1982; 15: 280-289
4. Klein D. Improvement of phase III psychotropic drug trials by intensive phase II work. Neuropsychopharmacology 1991; 4: 251-271
5. Sprafkin J, Gadow KD. Double-blind versus open evaluations of stimulant drug response in children with attention-deficit hyperactivity disorder. J of Child and Adolescent Psychopharmacology 1996; 6(4): 215-228
6. Brannen J, McEvoy JP, Wilson WH, Petrie W, Ban T, Berney S, Schaffer J. A double-blind comparison of Bromperidol and Haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatry 1981; 14: 139-140
7. Fleischhacker W, Unterweger B, Barnas C, Stuppäck C, Hinterhuber H. Results of an open phase II study with Zotepine - a new neuroleptic compound. Pharmacopsychiatry 1987; 20(Suppl. 1): 64-66
8. Sarai K, Okada M et al. Comparison of efficacy of Zotepine and Thiothixene in schizophrenia in a double-blind study. Pharmacopsychiatry 1987; 20(Suppl. 1): 38-46
9. Storosum J, Elferink AJA, van Zwieten BJ. Schizophrenia: Do we really need placebo-controlled studies? European Neuropsychopharmacology 1998; 8: 279-286
10. Pöldinger W, Bures E, Haage H. Clinical study with Bromperidol, a new butyrophenone derivative. Int Pharmacopsychiat 1977; 12: 20-24
11. Haase H, Kaumeier S, Schwarz H, Gundel A, Linde O et al. Open Study with Bromperidol, a new neuroleptic, for the determination of the neuroleptic treshold and the neuroleptic-therapeutic range. Pharmacopsychiatry 1978; 11: 81-85
12. Hucker H. Bericht über die Anwendung von Bromperidol im offenen Versuch. Int Pharmacopsychiat 1978; 13(Suppl. 1): 53-61
13. Psaras M, Paterakis P, Manafi T, Zissis N, Lyketsos G. Therapeutic evaluation of Bromperidol in schizophrenia: double-blind comparison with Chlorpromazine in chronic patients and open administration in schizophrenics with acute symptomatology. Current Therapeutic Research 1984; 36(6): 189-197
14. El-Assra A. Chronic Schizophrenia: a new butyrophenone for possible management. Medical Department, Janssen Pharmaceutical Department Ltd. Unpublished Manuscript
15. Bures E, Pöldinger W. Einleitende Worte zum Austausch der Erfahrungen über die klinische Wirkung von Bromperidol. Int Pharmacopsychiat 1978; 13(Suppl. 1): 45-52
16. Woggon B. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs. Acta Psychiat Belg 1978; 78: 155-172
17. Denijs E. Clinical evaluation of Bromperidol versus Haloperidol in psychotic patients. Int Pharmacopsychiat 1980; 15: 309-317
18. Hitoshi I. A comparison of the clinical effects of Bromperidol, a new butyrophenone derivative, and Haloperidol on schizophrenia using a double-blind technique. Psychopharmacol Bulletin 1985; 21(1): 120-122
19. Shopsin B, Selzer G. High-Dose Pimozide in acutely ill, newly admitted schizophrenic inpatients. Current Therapeutic Research 1977; 21(6): 755-767
20. Piyakulmala S, Corbett L, Ahluwalia Y, Berry R, Meltzer H. High dose Pimozide in the treatment of acutely agitated schizophrenia. Current Therapeutic Research 1977: 22(4): 453-461
21. Feinberg S, Kay SR, Elijovich LR, Fiszbein A, Opler L. Pimozide treatment of the negative schizophrenic syndrome: an open trial. J Clin Psychiatry 1988; 49(6): 235-238
22. Chouinard G, Annable L. Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology 1982; 76: 13-19
23. Haas S, Beckmann H. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatry 1982; 15: 70-74
24. The Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study. British Journal of Psychiatry 1987; 150: 334-338
25. Klieser E, Schröder HG, Goncalves J, Strauß W. Über die anti-psychotische Wirksamkeit von Remoxiprid, einem selektiven Dopaminantagonisten. Unveröffentlichtes Manuskript
26. Lindström L, Besev G, Stening G, Widerlöv E. An open study on Remoxipride, a benzamide derivate, in schizophrenia. Psychopharmacology 1985; 86: 241-243
27. McCreadie R, Morrison D, Eccleston D, Gall R, Loudon J, Mitchell M. An open multicentre study of the treatment of florid schizophrenia with Remoxipride. Acta Psychiatr Scand 1985; 72: 139-143
28. Chouinard G. Early phase II clinical trial of Remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J Clin Psychopharmacology 1987; 7(3): 159-164
29. DenBoer J, Verhoeven WMA, Westenberg HGM. Remoxipride in schizophrenia. A preliminary report. Acta Psychiatr Scand 1986; 4: 409-414
30. Hebenstreit G, Laux G, Schubert H, Beckmann H, Amman J, Bunse J, Eikmeier G, Geretsegger C. A double-blind comparative multicentre study of controlled-release Remoxipride, immediate-release Remoxipride and Haloperidol in schizophrenia. Pharmacopsychiatry 1991; 24: 153-158
31. Lapierre Y, Nair NPV, Chouinard G et al. A controlled dose-ranging study of Remoxipride and Haloperidol in schizophrenia - a Canadian multicentre trial. Acta Psychiatr Scand 1990; 82(Suppl. 358): 72-76
32. Ahlfors U, Rimon R, Appelberg B et al. Remoxipride and Haloperidol in schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand 1990; 82(Suppl. 358): 99-103
33. Andersen J, Korner A, Ostergaard P et al. A double blind comparative multicentre study of Remoxipride and Haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 82(Suppl. 358): 104-107
34. DenBoer J, Ravelli DP, Huisman J, Öhrvik J, Verhoeven W, Westenberg H. A double-blind comparative study of Remoxipride and Haloperidol in acute schizophrenia. Acta Psychiatr Scand 1990; 82(Suppl. 358): 108-110
35. Chouinard G. A placebo-controlled clinical trial of Remoxipride and Chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatr Scand 1990; 82(Suppl. 358): 111-119
36. Deo R. Remoxipride and Haloperidol in the acute phase of schizophrenia: a double-blind comparison. Acta Psychiatr Scand 1990; 82(Suppl. 358): 120-124
37. Laux G, Klieser E, Schröder HG et al. A double-blind multicentre study comparing Remoxipride, two and three times daily, with Haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 82(Suppl. 358): 125-129
38. Lindström L, Wiselgren IM, Struwe G et al. A double-blind comparative multicentre study of Remoxipride and Haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 82(Suppl. 358): 130-135
39. Mendlewicz L, deBleeker E, Cosyns P et al. A double-blind comparative study of Remoxipride and Haloperidol in schizophrenic and schizophreniform disorders. Acta Psychiatr Scand 1990; 82(Suppl. 358): 138-141
40. Pflug B, Bartels M, Bauer H et al. A double-blind multicentre study comparing Remoxipride, controlled-release formulation, with Haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 82(Suppl. 358): 142-146
41. Patris M, Agussol P, Alby JM et al. A double-blind multicentre comparison of Remoxipride, at two dose levels, and Haloperidol. Acta Psychiatr Scand 1990; 82(Suppl. 358): 78-82
42. Higashi Y, Momotani Y, Suzuki E, Kaku T. Clinical and EEG studies of Zotepine, a thiepine neuroleptic, on schizophrenic patients. Pharmacopsychiatry 1987; 20(Suppl. 1): 8-11
43. v Bardeleben U, Benkert O, Holsboer F. Clinical and neuroendocrine effects of Zotepine - a new neuroleptic drug. Pharmacopsychiatry 1987; 20(Suppl. 1): 28-34
44. Dieterle D, Ackenheil M, Müller-Spann F, Kapfhammer H. Zotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry 1987; 20(Suppl. 1): 52-57
45. Fleischhacker W, Barnas C, Stuppäck C, Unterweger B, Hinterhuber H. Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry 1987; 20(Suppl. 1): 58-60
46. Fleischhacker W, Barnas C, Stuppäck C, Sperner-Unterweger B, Miller C, Hinterhuber H. Zotepin versus Haloperidol bei paranoider Schizophrenie: eine Doppelblindstudie. Fortschr Neurol Psychiat 1991; 59(Suppl. 1): 10-13
47. Dieterle D, Müller-Spahn F, Ackenheil M. Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten. Fortschr Neurol Psychiat 1991; 59(Suppl. 1): 18-22
48. Wetzel H, v Bardeleben U, Holsboer F, Benkert O. Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppelblind-kontrollierte Wirksamkeitsprüfung. Fortschr Neurol Psychiat 1991; 59(Suppl. 1): 23-29
49. Sechter D, Caillard V, Cuche H, Deniker P. Open clinical study of cis(Z)-dopenthixol. Acta Psychiatr Scand 1981; 64(Suppl. 294): 20-24
50. König P, Seifert T, Eberhardt G. Findings with cis-Z-clopenthixol in the treatment of acute mania and schizophrenia. Pharmacopsychiatry 1986; 19(6): 424-428
51. Bereen F, Harte FB, Maguire J, Singh A. The use of oral Zuclopenthixol in the treatment of functional psychotic illnesses. Pharmatherapeutica 1987; 5: 62-68
52. Gravem A, Engstrand E, Guleng RJ. Cis(Z)-clopenthixol and clopenthixol in chronic psychotic patients. A double-blind investigation. Acta Psychiatr Scand 1978; 58: 384-388
53. Gravem A, Bugge A. Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses. Acta Psychiatr Scand 1981; 64(Suppl. 294): 13-19
54. Heikkilae L, Rarsten D, Valli K. A double-blind clinical investigation of cis(Z)-clopenthixol and clopenthixol in chronic schizophrenic patients. Acta Psychiatr Scand 1981; 64(Suppl. 294): 25-29
55. Heikkilae L, Laitinen J, Vartiainen H. Cis(Z)-clopenthixol and Haloperidol in chronic schizophrenic patients - a double-blind clinical multicentre investigation. Acta Psychiatr Scand 1981; 64(Suppl. 294): 303
56. Woggon B. Cis(Z)-clopenthixol in der Behandlung der akuten Schizophrenien. Kopenhagen: Clopixol Symposium, 1983
57. Heikkilae L, Eliander H, Vartiainen H et al. Zuclopenthixol and Haloperidol in patients with acute psychotic states. A double-blind multicentre study. Current Medical Research and Opinion 1992; 12(9): 594-603